Nanjing Bioheng Biotech Co., Ltd.
Clinical trials sponsored by Nanjing Bioheng Biotech Co., Ltd., explained in plain language.
-
Early trial tests One-Shot cell therapy for eight serious autoimmune conditions
Disease control TerminatedThis early-phase study aimed to test the safety and initial effects of a new cell therapy called RD06-04 for people with serious autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis. The therapy involves modifying a patient's own immune cells (CAR-T cells) to…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Experimental cell therapy targets Hard-to-Treat autoimmune diseases
Disease control TerminatedThis early-stage study is testing the safety and initial effects of a new cell therapy called RD06-04 for people with active, severe autoimmune diseases. The therapy involves modifying a patient's own immune cells (CAR-T cells) to target and remove certain harmful immune cells. T…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC